Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 73

1.

The antithrombotic and haemostatic effects of LASSBio-752: a synthetic, orally active compound in an arterial and venous thrombosis model in rats.

Frattani FS, Lima LM, Barreiro EJ, Zingali RB.

J Pharm Pharmacol. 2017 Oct;69(10):1374-1380. doi: 10.1111/jphp.12771. Epub 2017 Jul 19.

PMID:
28722151
2.

Antithrombotic efficacy of thrombin inhibitor L-374,087: intravenous activity in a primate model of venous thrombus extension and oral activity in a canine model of primary venous and coronary artery thrombosis.

Cook JJ, Gardell SJ, Holahan MA, Sitko GR, Stump GL, Wallace AA, Gilberto DB, Hare TR, Krueger JA, Dyer DL, Sanderson PE, Vacca JP, Shafer JA, Lynch JJ Jr.

J Pharmacol Exp Ther. 1999 Apr;289(1):503-10.

PMID:
10087043
3.

The antithrombotic efficacy of AT-1459, a novel, direct thrombin inhibitor, in rat models of venous and arterial thrombosis.

Cho JH, Yun CH, Seo HS, Koga T, Dan T, Koo BA, Kim HY.

Thromb Haemost. 2001 Dec;86(6):1512-20.

PMID:
11776321
4.

The arterial antithrombotic activity of thioxylosides in a rat model of laser-induced thrombosis.

Aguejouf O, Oualane FA, Inamo J, Imbault P, Doutremepuich F, Millet J, Theveniaux J, Doutremepuich C.

Semin Thromb Hemost. 1996;22(4):327-33.

PMID:
8944417
5.

Repeated doses of oral and subcutaneous heparins have similar antithrombotic effects in a rat carotid arterial model of thrombosis.

Hiebert LM, Ping T, Wice SM.

J Cardiovasc Pharmacol Ther. 2012 Mar;17(1):110-6. doi: 10.1177/1074248411405991. Epub 2011 Apr 21.

PMID:
21512111
6.

The antithrombotic effects of CI-1028, an orally bioavailable direct thrombin inhibitor, in a canine model of venous and arterial thrombosis.

McClanahan TB, Hicks GW, Ignasiak DP, Bousley R, Mertz TE, Juneau P, Janiczek-Dolphin N, Kim IC, Gallagher KP.

J Thromb Thrombolysis. 2000 Dec;10(3):277-84.

PMID:
11122549
7.

Evaluation of AR-H067637, the active metabolite of the new direct thrombin inhibitor AZD0837, in models of venous and arterial thrombosis and bleeding in anaesthetised rats.

Pehrsson S, Johansson K, Kjaer M, Elg M.

Thromb Haemost. 2010 Dec;104(6):1242-9. doi: 10.1160/TH09-10-0744. Epub 2010 Aug 30.

PMID:
20806126
8.

Aliskiren inhibits experimental venous thrombosis in two-kidney one- clip hypertensive rats.

Hermanowicz JM, Hermanowicz A, Buczko P, Leszczynska A, Tankiewicz-Kwedlo A, Mogielnicki A, Buczko W.

Thromb Res. 2013 Jan;131(1):e39-44. doi: 10.1016/j.thromres.2012.11.001. Epub 2012 Nov 20.

PMID:
23174623
9.

Oral antithrombotic effects of acylhydrazone derivatives.

Frattani FS, Coriolano EO, Lima LM, Barreiro EJ, Zingali RB.

J Atheroscler Thromb. 2013;20(3):287-95. Epub 2012 Nov 27.

10.

Comparison of antithrombotic and haemorrhagic effects of edoxaban, an oral direct factor Xa inhibitor, with warfarin and enoxaparin in rats.

Morishima Y, Honda Y, Kamisato C, Tsuji N, Kita A, Edo N, Shibano T.

Thromb Res. 2012 Sep;130(3):514-9. doi: 10.1016/j.thromres.2012.05.008. Epub 2012 May 29.

PMID:
22647432
11.

Antithrombotic effects of (n-3) polyunsaturated fatty acids in rat models of arterial and venous thrombosis.

Andriamampandry MD, Leray C, Freund M, Cazenave JP, Gachet C.

Thromb Res. 1999 Jan 1;93(1):9-16.

PMID:
10065894
12.

Antithrombotic potential of new direct thrombin inhibitors built on the azaphenylalanine scaffold in two rat venous thrombosis models.

Peternel L, Stegnar M, Drevensek G, Budihna MV, Bozic M, Zega A, Stalc A, Cerne M, Urleb U.

Thromb Haemost. 2005 Mar;93(3):437-42.

PMID:
15735792
13.

Comparative study on the in vitro and in vivo activities of heparinoids derivative investigated on the animal model.

Giedrojć J, Klimiuk M, Radziwon P, Kłoczko J, Bielawiec M, Breddin HK.

J Cardiovasc Pharmacol. 1999 Sep;34(3):340-5.

PMID:
10470990
14.

A new recombinant thrombolytic and antithrombotic agent with higher fibrin affinity - a staphylokinase variant. An in-vivo study.

Szemraj J, Stankiewicz A, Rozmyslowicz-Szermińska W, Mogielnicki A, Gromotowicz A, Buczko W, Oszajca K, Bartkowiak J, Chabielska E.

Thromb Haemost. 2007 Jun;97(6):1037-45.

PMID:
17549308
15.

Partial versus complete factor VIII inhibition in a mouse model of venous thrombosis.

Emmerechts J, Vanassche T, Loyen S, Van Linthout I, Cludts K, Kauskot A, Long C, Jacquemin M, Hoylaerts MF, Verhamme P.

Thromb Res. 2012 Apr;129(4):514-9. doi: 10.1016/j.thromres.2011.06.027. Epub 2011 Jul 20.

PMID:
21777952
16.

Antithrombotic potential of GW813893: a novel, orally active, active-site directed factor Xa inhibitor.

Abboud MA, Needle SJ, Burns-Kurtis CL, Valocik RE, Koster PF, Amour AJ, Chan C, Brown D, Chaudry L, Zhou P, Patikis A, Patel C, Pateman AJ, Young RJ, Watson NS, Toomey JR.

J Cardiovasc Pharmacol. 2008 Jul;52(1):66-71. doi: 10.1097/FJC.0b013e31817e9b9e.

PMID:
18645410
17.

Antithrombotic and hemostatic effects of a small molecule factor XIa inhibitor in rats.

Schumacher WA, Seiler SE, Steinbacher TE, Stewart AB, Bostwick JS, Hartl KS, Liu EC, Ogletree ML.

Eur J Pharmacol. 2007 Sep 10;570(1-3):167-74. Epub 2007 Jun 5.

PMID:
17597608
18.

Antithrombotic properties of water-soluble carbon monoxide-releasing molecules.

Kramkowski K, Leszczynska A, Mogielnicki A, Chlopicki S, Fedorowicz A, Grochal E, Mann B, Brzoska T, Urano T, Motterlini R, Buczko W.

Arterioscler Thromb Vasc Biol. 2012 Sep;32(9):2149-57. doi: 10.1161/ATVBAHA.112.253989. Epub 2012 Jul 5.

19.

NP-184[2-(5-methyl-2-furyl) benzimidazole], a novel orally active antithrombotic agent with dual antiplatelet and anticoagulant activities.

Kuo HL, Lien JC, Chung CH, Chang CH, Lo SC, Tsai IC, Peng HC, Kuo SC, Huang TF.

Naunyn Schmiedebergs Arch Pharmacol. 2010 Jun;381(6):495-505. doi: 10.1007/s00210-010-0505-x. Epub 2010 Mar 27.

PMID:
20349046
20.

A small-molecule factor XIa inhibitor produces antithrombotic efficacy with minimal bleeding time prolongation in rabbits.

Wong PC, Crain EJ, Watson CA, Schumacher WA.

J Thromb Thrombolysis. 2011 Aug;32(2):129-37. doi: 10.1007/s11239-011-0599-0.

PMID:
21614454

Supplemental Content

Support Center